CV Risk Biomarkers Tentatively Identified in Psoriatic Disease
The risk of cardiovascular events in patients with psoriatic disease rises with higher levels of two cardiac biomarkers in a manner independent of risk calculated by the Framingham Risk Score (FRS), a longitudinal cohort study has shown. But researchers who conducted the study note that neither of the two biomarkers identified in the study ― cardiac troponin I (cTnI) and N-terminal pro-brain-type natriuretic peptide (NT-proBNP) ― led to an improvement in predictive performance when combined with the FRS, despite their association with carotid plaque burden.
@minti Psoriasis and psoriatic arthritis are both associated with greater risk of cardiovascular morbidity and mortality, partly because of systemic inflammation that leads to atherogenesis. Measures of cardiovascular risk such as the FRS rely on traditional measures of cardiovascular risk and thus are likely to underestimate the cardiovascular event risk of people with psoriatic disease